NASDAQ · AHCO
Healthcare · Medical - Devices
$5.82
Up+$0.01 (+0.17%)
Updated Aug 19, 2026, 5:08 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AHCO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning AHCO.
AHCO research
Company profile and research snapshot.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | UBS | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
| Jul 21, 2026 | Jefferies | Buy | — |
| Jul 6, 2026 | Baird | Outperform | — |
No generated briefing is available yet.
Yahoo · Aug 7, 2026
CONSHOHOCKEN, Pa., August 07, 2026--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the following upcoming investor conferences:
ChartMill · Aug 7, 2026
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Benzinga · Aug 6, 2026
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.
Benzinga · Aug 6, 2026
RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $15 to $8.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AHCO.
